News

Breakthrough results on VAX-ID for kids at 12th Vaccine Conference

Posted on 15/09/2018

Timothi Van Mulder will present Novosanis' breakthrough results on the development of a painless injection device for children at 12 th Vaccine Congress in Budapest, Hungary from September...

Novosanis attending Life Sciences week and BioJapan

Posted on 12/10/2016

Novosanis will present its VAX-ID™ device platform during BioJapan

Research on skin thickness published by Van Mulder and co-workers in prestigious journal 'Vaccine'

Posted on 25/08/2016

"High Frequency Ultrasound to Assess Skin Thickness in Healthy Adults” published in the prestigious peer-reviewed journal VACCINE.

VAX-ID by Novosanis to be used in Phase 1 vaccination trial by ImevaX

Posted on 26/07/2016

Novosanis announced today their collaboration with ImevaX, a biopharmaceutical company based in Munich, Germany

You are here

Breakthrough results on VAX-ID for kids at 12th Vaccine Conference

Novosanis attending Life Sciences week and BioJapan

Research on skin thickness published by Van Mulder and co-workers in prestigious journal 'Vaccine'

VAX-ID by Novosanis to be used in Phase 1 vaccination trial by ImevaX

Pages

novosanis